Page 12 - Flipbook

Characteristics Balar et al/Pembro Del Muro et al/Durva+Treme Galsky et al/Nivo

n 54 32 76

Follow-up 15.5 months (1.6 – 56.5 m) 12.7 months (5.3 – 24.5 m) 13.7 months (2.5 – 24 m)

Gender (male) 72% 78% 79%

Clinical stage T2 – 70% T2 – 87% T2 – 57%

T3 – 26% T3 – 9% T3 – 32%
T4 – 4% T4 – 3% T4 – 12%

Histology Pure UC – 97% Pure UC – 63% Pure UC – 76%

Prior NMIBC 19% (BCG: 12%) 44% (BCG: 25%) N/A

Response

CR 32 (59%) 26 (81%) 31 (48%)**

T0 response: 25 (78%)

NMIBC: 1 (3%)

Not evaluated 11 (20%) – all clinically with 4 (12.5%)

no evidence of disease

(clinical CR: 80%)

1-yr BIDFS in pts with CR 89% (95% CI 76-95%) 73% (95% CI 59-91%) 78% (95% CI 54-30%)

** Local recurrence occurred in 8/31 cCR pts

Radiation Oncology